Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EA-230 in on-pump cardiac surgery
NL-OMON42527Phase 2Recruiting
- Sponsor
- Exponential Biotherapies, Inc.
- Start
- Jul 2016
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Systemic Inflammatory Response Syndrome (SIRS) comparing EA-230 with Placebo (2 arms). Primary endpoints: Adverse events, Vital signs and 1 more. Started Jul 2016; status: recruiting.
02
Drugs
EA-230
03
Conditions
Systemic Inflammatory Response Syndrome (SIRS)
Beyond the preview
Go deeper on NL-OMON42527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42527.